Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atropine sulphate - Ocumension

Drug Profile

Atropine sulphate - Ocumension

Alternative Names: OT-101 - Ocumension; OT-101-S

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocumension Therapeutics
  • Class Alkaloids; Antidotes; Cardiovascular therapies; Eye disorder therapies; Small molecules; Tropanes
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Myopia

Most Recent Events

  • 21 Mar 2024 NMPA accepts phase III clinical trial application for OT-101-S (0.01% and 0.05% atropine sulfate eye drops) in Myopia in China .
  • 21 Mar 2024 Ocumension completes enrolment in the phase-III clinical trials in Myopia (In children, In adolescents) in USA, China, United Kingdom (Ophthalmic) (NCT04770610)
  • 20 Apr 2022 Ocumension has multiple patent protections for atropine sulphate in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top